A practical approach to the diagnosis and management of MELAS: Case report and review

Neurologist

Volumn 8, Issue 5, 2002, Pages 302-312

  Thambisetty, Madhav ^a   Newman, Nancy J ^a   Glass, Jonathan D ^a   Frankel, Michael R ^a  

^a EMORY EYE CENTER   (United States)

Author keywords

Computed tomography; Encephalopathy; Magnetic resonance imaging; MELAS; Mitochondria; Mutation; Ragged red fibers; Seizures; Stroke; Weakness

Indexed keywords

ASCORBIC ACID; MENADIONE; MITOCHONDRIAL DNA; MITOCHONDRIAL ENZYME; UBIQUINONE;

ADULT; AEROBIC METABOLISM; ARTICLE; BRAIN DISEASE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC COUNSELING; HUMAN; HUMAN CELL; HUMAN TISSUE; LACTIC ACIDOSIS; MALE; MELAS SYNDROME; MITOCHONDRIAL RESPIRATION; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; SEIZURE; SKELETAL MUSCLE; STROKE;

EID: 0036741806     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00127893-200209000-00003     Document Type: Article

References (74)

1. Pavlakis SG, Phillips PC, DiMauro S, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes: a distinctive clinical syndrome. Ann Neurol. 1984;16:481-488.
2. Schon EA, Bonilla E, DiMauro S. Mitochondrial DNA mutations and pathogenesis. J Bioenerg Biomembr. 1997;29:131-149.
3. Shanske S, DiMauro S. Diagnosis of the mitochondrial encephalomyopathies. Curr Opin Rheum. 1997;9:496-503.
4. Hirano M, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS): current concepts. J Child Neurol. 1994;9:4-13.
5. Goto Y, Horai S, Matsuoka T, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology. 1992;42:545-550.
6. Ciafaloni E, Ricci E, Shanske S, et al. MELAS: clinical features, biochemistry, and molecular genetics. Ann Neurol 1992;31:391-398.
7. Hasegawa H, Matsuoka T, Goto Y, et al. Strongly succinate dehydrogenase-reactive blood vessels in muscles from patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Ann Neurol. 1991;29:601-605.
8. Ballinger SW, Schoffner JM, Hedaya EV, et al. Maternally transmitted diabetes and deafness associated with a 10.4kb mitochondrial DNA deletion. Nat Genet. 1992;1:11-15.
9. Berenberg RA, Pellock JM, DiMauro S, et al. Lumping or splitting? "Ophthalmoplegia-plus" or Kearns-Sayre syndrome? Ann Neurol 1977; 1:37-54.
10. Berkovic SF, Carpenter S, Evans A, et al. Myoclonus, epilepsy and ragged-red fibres (MERRF), I: a clinical, pathological, biochemical, magnetic resonance spectrographic and positron emission tomographic study. Brain. 1989;112:1231-1260.
11. Sue CM, Lipsett LJ, Crimmins DS, et al. Cochlear origin of hearing loss in MELAS syndrome. Ann Neurol. 1998;43:350-359.
12. Taivassalo T, De Stefano N, Argov Z, et al. Effects of aerobic training in patients with mitochondrial myopathies. Neurology. 1998;50:1055-1060.
13. Kadowaki T, Kadowaki H, Mori Y, et al. A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med. 1994;330:962-968.
14. Ohkoshi N, Ishii A, Shiraiwa N, et al. Dysfunction of the hypothalamic-pituitary system in mitochondrial encephalomyopathies. J Med. 1998;29:13-29.
15. Balestri P, Grosso S. Endocrine disorders in two sisters affected by MELAS syndrome. J Child Neurol. 2000;15:755-758.
16. Yang CY, Lam HC, Lee HC, et al. MELAS syndrome associated with diabetes mellitus and hyperthyroidism: a case report from Taiwan. Clin Endocrinol. 1995;43:235-239.
17. Leu(UUR) mutation. J Med Genet. 1996;33:621-622.
18. Okajima Y, Tanabe Y, Takayanagi M, et al. A follow up study of myocardial involvement in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. Heart. 1998;80:292-295.
19. Zupanc ML, Moraes CT, Shanske S, et al. Deletion of mitochondrial DNA in patients with combined features of Kearns-Sayre and MELAS syndromes. Ann Neurol. 1991;29:680-683.
20. Latkany P, Ciulla TA, Cacchillo PF, et al. Mitochondrial maculopathy: geographic atrophy of the macula in the MELAS associated A to G 3243 mitochondrial DNA point mutation. Am J Ophthalmol. 1999;128:112-114.
21. Fang W, Huang C-C, Lee C-C, et al. Ophthalmologic manifestations in MELAS syndrome. Arch Neurol. 1993;50:977-980.
22. Biousse V, Newman NJ. Neuro-ophthalmology of mitochondrial diseases. Semin Neurol. 2001;21:275-291.
23. Sue CM, Crimmins DS, Soo YS, et al. Neuroradiological features of six kindreds with MELAS tRNA(Leu) A2343G point mutation: implications for pathogenesis. J Neurol Neurosurg Psych. 1998;65:233-240.
24. Yamamoto T, Beppu H, Tsubaki T. Mitochondrial encephalomyopathy: fluctuating symptoms and CT. Neurology. 1984; 34:1456-1460.
25. Matthews PM, Tampieri D, Berkovic SF, et al. Magnetic resonance imaging shows specific abnormalities in the MELAS syndrome. Neurology. 1991;41:1043-1046.
26. Yoneda M, Maeda M, Kimura H, et al. Vasogenic edema on MELAS: a serial study with diffusion-weighted MR imaging. Neurology. 1999; 53:2182-2184.
27. Schlaug G, Siewert B, Benfield A, et al. Time course of the apparent diffusion coefficient (ADC) abnormality in human stroke. Neurology. 1997;49:113-119.
28. Oppenheim C, Galanaud D, Samson Y, et al. Can diffusion weighted magnetic resonance imaging help differentiate stroke from stroke-like events in MELAS? J Neurol Neurosurg Psychiatry. 2000;69:248-250.
29. Ohama E, Ohara S, Ikuta F, et al. Mitochondrial angiopathy in cerebral blood vessels of mitochondrial encephalomyopathy. Acta Neuropathol. 1987;74:226-233.
30. Tanahashi C, Nakayama A, Yoshida M, et al. MELAS with the mitochondrial DNA 3243 point mutation: a neuropathological study. Acta Neuropathol. 2000;99:31-38.
31. Matthews PM, Andermann F, Silver K, Karpati G, et al. Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology. 1993; 43:2484-2490.
32. Wilichowski E, Pouwels PJ, Frahm J, et al. Quantitative proton magnetic spectroscopy of cerebral metabolic disturbances in patients with MELAS. Neuropediatrics. 1999;30:256-263.
33. Goto YI. Clinical features of MELAS and mitochondrial DNA mutations. Muscle Nerve. 1995;3:S107-S112.
34. Moraes CT, Ricci E, Bonilla E, et al. The mitochondrial tRNA Leu (UUR) mutation in mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS): genetic, biochemical, and morphological correlations in skeletal muscles. Am J Hum Genet. 1992; 50:934-939.
35. Matsuoka T, Goto Y, Yoneda M, et al. Muscle histopathology in myoclonus epilepsy with ragged-red fibers (MERRF). J Neurol Sci. 1991;106:193-198.
36. Goto Y, Koga Y, Horai S, et al. Chronic progressive external ophthalmoplegia: a comparative study of mitochondrial DNA deletions and their phenotypic expression in muscle biopsies. J Neurol Sci. 1990; 100:63-69.
37. Holt IJ, Harding AE, Cooper JM, et al. Mitochondrial myopathies: clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA. Ann Neurol. 1989;26:699-708.
38. Hirano M, Ricci E, Rowland LP, et al. Clinical definition of MELAS. Ann Neurol. 1991;30:299.
39. Ruitenbeek W, Wendel U, Hamel BCJ, et al. Genetic counselling and prenatal diagnosis in disorders of the mitochondrial energy metabolism. J Inher Metab Dis. 1996;19:581-587.
40. Johns DR. Seminars in medicine of the Beth Israel Hospital. Boston: mitochondrial DNA and disease. N Engl J Med. 1995;333:638-644.
41. Wallace DC. Diseases of the mitochondrial DNA. Annu Rev Biochem. 1992;61:1175-1212.
42. Goto Y, Tsugane K, Tanabe Y, et al. A new point mutation at nucleotide pair 3291 of the mitochondrial tRNA (Leu(UUR)) gene in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Biochem Biophys Res Commun. 1994; 202:1624-1630.
43. Goto Y, Nonaka I, Horai S. A new mtDNA mutation associated with mitochondrial myopathy encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Biochem Biophys Acta. 1991;1097:238-240.
44. Sato W, Hayasaka K, Shoji Y, et al. A mitochondrial tRNA(leu)(UUR) mutation at 3256 associated with mitochondrial myopathy encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Biochem Mol Biol Int. 1994;33:1055-1061.
45. Morten KJ, Cooper JM, Brown GK, et al. A new point mutation associated with mitochondrial encephalomyopathy. Hum Mol Genet. 1993;2:2081-2087.
46. Taylor RW, Chinnery PF, Haldane F, et al. MELAS associated with a mutation in the valine transfer RNA gene of mitochondrial DNA. Ann Neurol. 1996;40:459-462.
47. Lertrit P, Noer AS, Jean-Francois MJ, et al. A new disease-related mutation for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome affects the ND4 subunit of the respiratory complex I. Am J Hum Genet. 1992;51:457-468.
48. Bataillard M, Chatzoglou E, Rumbach L, et al. Atypical MELAS syndrome associated with a new mitochondrial tRNA glutamine point mutation. Neurology. 2001;56:405-407.
49. de Coo IF, Sistermans EA, de Wijs IJ, et al. A mitochondrial tRNA(Val) gene mutation (G1642A) in a patient with mitochondrial myopathy, lactic acidosis, and stroke-like episodes. Neurology. 1998;50:93-95.
50. Santorelli FM, Tanji K, Kulikova R, et al. Identification of a novel mutation in the mtDNA ND5 gene associated with MELAS. Biochem Biophys Res Commun. 1997;238:326-328.
51. lys gene. Eur J Hum Genet. 1993;1:80-87.
52. ser gene detected in a family with MERRF/MELAS overlap syndrome. Biochem Biophys Res Commun. 1995;214:86-93.
53. Pulkes T, Eunson L, Patterson V, et al. The mitochondrial DNA G13513A transition in ND5 is associated with a LHON/MELAS overlap syndrome and may be a frequent cause of MELAS. Ann Neurol. 1999;46:916-919.
54. Kearns TP, Sayre GP. Arch Ophthamol. 1958;60:280-289.
55. Zeviani M, Moraes CT, DiMauro S, et al. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology. 1998;5:1525-1533.
56. Zupanc ML, Moraes CT, Shanske S, et al. Deletion of mitochondrial DNA in patients with combined features of Kearns-Sayre and MELAS syndromes. Ann Neurol. 1991;29:680-683.
57. Campos Y, Garcia-Silva T, Barrionuevo CR, et al. Mitochondrial DNA deletion in a patient with mitochondrial myopathy, lactic acidosis and stroke-like episodes (MELAS) and Fanconi's syndrome. Pediatr Neurol. 1995;13:69-72.
58. Dimauro S. Mitochondrial encephalomyopathies: what next? J Inher Metab Dis. 1996;19:489-503.
59. Schoffner JM. Oxidative phosphorylation disease. In: Johnson RT, Griffin JW, eds. Current Therapy in Neurological Disease. Chicago: Mosby; 1997:332-342.
60. Bresolin N, Doriguzzi C, Ponzetto C, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci. 1990;100:70-78.
61. Abe K, Fujimura H, Nishikawa Y, et al. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Acta Neurol Scand. 1991;83:356-359.
62. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies: short-term double-blind, crossover study. Eur Neurol. 1997;37:212-218.
63. Goda S, Hamada T, Ishimoto S, et al. Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol. 1987;234:62-63.
64. Abe K, Matsuo Y, Kadekawa J, et al. Effect of coenzyme Q10 in patients with mitochondrial myopathy encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): evaluation by noninvasive tissue oximetry. J Neurol Sci. 1999;162:65-68.
65. Stacpoole PW, Greene YJ. Dichloroacetate. Diabetes Care. 1992;15: 785-791.
66. Stacpoole PW, Lorenz AC, Thomas RG, et al. Dichloroacetate in the treatment of lactic acidosis. Ann Intern Med. 1988;108:58-63.
67. De Stefano N, Matthews PM, Ford B, et al. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology. 1995;45:1193-1198.
68. Pavlakis SG, Kingsley PB, Kaplan GP, et al. Magnetic resonance spectroscopy: use in monitoring MELAS treatment. Arch Neurol. 1998; 55:849-852.
69. Saijo T, Naito E, Ito M, et al. Therapeutic effect of sodium dichloroacetate on visual and auditory hallucinations in a patient with MELAS. Neuropediatrics. 1991;22:166-167.
70. Saitoh S, Momoi MY, Yamagata T, et al. Effects of dichloroacetate in three patients with MELAS. Neurology. 1998;50:531-534.
71. Kuroda Y, Ito M, Naito E, et al. Concomitant administration of sodium dichloroacetate and vitamin B sub 1 for lactic acidemia in children with MELAS syndrome. J Pediatr. 1997;131:450-452.
72. Calvani M, Koverech A, Caruso G. Treatment of mitochondrial diseases. In: DiMauro S, Wallace DC, eds. Mitochondrial DNA in Human Pathology. New York: Raven Press; 1993:173-198.
73. Argov Z, Bank WJ, Maris J, et al. Treatment of nutochondrial myopathy due to complex II deficiency with vitamins K3 and C: a 31P-NMR follow-up study. Ann Neurol. 1986;19:598-602.
74. Chinnery PF, Howell N, Lightowlers RN, et al. MELAS and MERRF. The relationship between maternal mutation load and the frequency of clinically affected offspring. Brain. 1998;121:1889-1894.